Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line
✍ Scribed by Sanae Bennis; François Ichas; Jacques Robert
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- French
- Weight
- 901 KB
- Volume
- 62
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We studied the restoration of doxorubicin accumulation and sensitivity by verapamil and quinine in a variant of the human erythroleukemia cell line K562 selected for resistance to doxorubicin and presenting a multidrug‐resistance (MDR) phenotype. Verapamil was able to completely restore doxorubicin accumulation in the resistant cells to the level obtained in sensitive cells, but only partially reversed doxorubicin resistance. Quinine, in contrast, had a relatively weak effect on doxorubicin accumulation but was able to completely restore doxorubicin sensitivity in the resistant cells. In addition, verapamil was able to decrease azidopine binding to P‐glycoprotein, whereas quinine was not. Quinine also modified the intracellular tolerance to doxorubicin, which suggests that it is able to modify drug distribution within the cells. Confocal microscopy revealed that verapamil and quinine were able to restore nuclear fluorescence staining of doxorubicin in resistant cells; since this was obtained for quinine without significant increase of doxorubicin accumulation, this observation confirms that quinine acts principally on doxorubicin redistribution within the cells, allowing the drug to reach its nuclear targets. When used in association, verapamil and quinine reversed doxorubicin resistance in a synergistic fashion. We conclude that verapamil and quinine do not share the same targets for reversal of MDR in this cell line; whereas verapamil directly interferes with P‐glycoprotein and mainly governs drug accumulation, quinine has essentially intracellular targets involved in drug redistribution from sequestration compartments. © 1995 Wiley‐Liss Inc.
📜 SIMILAR VOLUMES
## Abstract The development of non‐P‐glycoprotein‐mediated multidrug resistance is a frequent event among lung‐cancer cell lines. In an attempt to understand the underlying mechanisms of this phenotype, we have selected a multi‐drug‐resistant subline (POGB/DX) __in vitro__ for doxorubicin resistanc
## Abstract A doxorubicin‐resistant variant of the human small‐cell lung‐cancer cell line N592 was selected by __in vitro__ continuous exposure to increasing drug concentrations. The aim of this study was to examine the cross‐resistance pattern, cellular pharmacokinetics of doxorubicin and expressi
A possible novel mechanism of cross-resistance to cisplatin (CDDP) in the doxorubicin-resistant ovarian-cancer cell line A2780-DX3, which displays atypical multidrug resistance, is presented. A2780-DX3 is found to be more resistant than the parental line A2780 in terms of CDDP-induced cytotoxicity a